Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 3:30 PM ET.

A live webcast of the event will be available on the "Events & Presentations" page on the Company's website. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.

About Gemini Therapeutics

Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Gemini’s lead candidate, GEM103, is a recombinant form of human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies and is advancing a potentiating antibody for CFH, GEM307, into clinical development for treatment of systemic diseases.

For more information, visit www.geminitherapeutics.com.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  221.09
+3.14 (1.44%)
AAPL  259.58
+1.13 (0.44%)
AMD  234.99
+4.76 (2.07%)
BAC  51.76
+0.66 (1.29%)
GOOG  253.73
+1.20 (0.48%)
META  734.00
+0.59 (0.08%)
MSFT  520.56
+0.02 (0.00%)
NVDA  182.16
+1.88 (1.04%)
ORCL  280.07
+7.41 (2.72%)
TSLA  448.98
+10.01 (2.28%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.